Anaplastic Large Cell Lymphoma, Vinorelbine
Conditions
Keywords
Anaplastic Large Cell Lymphoma, Childhood, Adolescent, Recurrent, Treatment
Brief summary
The purpose of this study is to assess the efficiency and safety of vinorelbine in the treatment of relapsed / advanced ALCL in children and adolescents.
Detailed description
Anaplastic large cell lymphoma (ALCL) is a rare non-Hodgkin's lymphoma, around 30% patients would get relapse. Vinorelbine(Navelbine) is a third-line treatment option for Hodgkin's disease(HD) after transplantation failed, while both HD and ALCL express CD30. When ALCL recurred, vinblastine monotherapy was used and the 5-year EFS up to 30%, 5-year OS up to 60%. In China vinblastine is unavailable. Vinorelbine is very similar to vinblastine in molecular formula, and is available in China. From November 2016 to March 2017, two patients with recurrent ALCL were recruited in the Department of Hematology and Oncology, Shanghai Children's Medical Center. They received vinorelbine monotherapy and achieved clinical remission (PET CR) at 8 weeks. One patient with bone marrow recurrence showed negative ALK / NPM by PCR . Based on this, the investigators will expand the sample to further investigate the therapeutic efficiency and safety of vinorelbine in children and adolescents with ALCL.
Interventions
DRUGVinorelbine
Vinorelbine will be used 25mg/m2/week, rest for 1 week after 3 weeks of continuous use, 4 weeks will be a course. After 1 week there will be a simple assessment, after 2 weeks will be a comprehensive assessment. If the patient got disease progression or partial response/stable disease, he/she would be removed from this trial.
Sponsors
Children's Cancer Group, China
Study design
Allocation
NON_RANDOMIZED
Intervention model
SINGLE_GROUP
Primary purpose
TREATMENT
Masking
NONE
Eligibility
Sex/Gender
ALL
Age
No minimum to 18 Years
Healthy volunteers
No
Inclusion criteria
Children and adolescents with a clear diagnosis of recurrent / progressive ALCL at Shanghai Children's Medical Center or other centers since September 2017 include: * Diagnosed as ALCL, already received first-line treatment, but get disease progression; * After receiving ALCL treatment has got CR then diagnosed relapse, need for pathological diagnosis.
Exclusion criteria
* Patients with other systemic diseases, severe infections or critically illness.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Event free survival | 5 years |
Secondary
| Measure | Time frame |
|---|---|
| Overall survival | 5 years |
Other
| Measure | Time frame | Description |
|---|---|---|
| Safety statistics: adverse reactions during the trial through NCI CTCAE version 4.0. | 2 years | The investigators will record the adverse reactions during the trial through NCI CTCAE version 4.0. |
Countries
China
Outcome results
None listed